Transgene SA · EURONEXT:TNG

Transgene SA — EASL Liver Congress 2015

13 slides from Transgene SA's conference presentation, Apr 23, 2015

  1. Slide 1: TG1050 can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models

    TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS Karine Lélu1, Alexei Evlachev1, Roland Kratzer1, Sarah Dion2, Maryline Mancini-Bourgine2, Ophélie Godon1,2, Doris Schmitt3, Clarisse Dubois1, Jean-Françoi

  2. Slide 2: Rationale for an immunotherapeutic in the treatment of chronic hepatitis B

    RATIONALE FOR AN IMMUNOTHERAPEUTIC IN THE TREATMENT OF CHRONIC HEPATITIS B (CHB)  HBV cure (HBsAg/anti-HBsAg seroconversion) rate is low with current therapies (3 to 5%)  Small molecules aiming at treating CHB do not recruit the host immune system yet:  A strong correlation exists between HBV spe

  3. Slide 3: TG1050: Product Description

    TG1050: PRODUCT DESCRIPTION TG1050 Based on non-replicative E1 and E3 deleted human adenovirus serotype 5 encoding a fusion protein comprising truncated HBV Core fused to a deleted and mutated HBV polymerase and 2 selected HBsAg (Env) domains (genotype D sequence) 1 832 Core t Pol1 Env 1 Pol2 Env 2

  4. Slide 4: Key features of TG1050 immunogenicity in HBV-free models

    KEY FEATURES OF TG1050 IMMUNOGENICITY IN HBV-FREE MODELS  In HBV-free mice, TG1050 injected once by sc route induces High frequencies of HBV-specific T cells targeting the 3 encoded HBV antigens Being mainly CD8+ T cells (detected in spleens and/or livers) Producing cytokines Displaying in vivo cyt

  5. Slide 5: AAV-HBV: a murine model of HBV persistence

    AAV-HBV : A MURINE MODEL OF HBV PERSISTENCE Long term persistence of viral parameters (up to 1 year) HLA-A2/DR1 mice OR iv injection HBV infectious C57BL/6J mice (5.1010 vg) HBcAg Liver viral particles DNA AAV2/8-HBV intermediates HBeAg 1.2 copies of HBV genome (genotype D) Spleen HBsAg Blood Immune

  6. Slide 6: AAV-HBV murine model and TG1050 immunization

    AAV-HBV MURINE MODEL AND TG1050 IMMUNIZATION ● AAV-HBV and TG1050 Injections ● Mice (HLA-A2/DR1 or C57BL/6J) are transduced by the AAV-HBV ● 32 days post-transduction, mice are immunized with TG1050 (once or multiple times) Example of protocol TG1050 AAV-HBV TG1050 Day 0 11 28 32 39 46 47 54 55 62 6

  7. Slide 7: TG1050 induces functional T cells specific of HBV in the liver of HBV persistent mice

    TG1050 INDUCES FUNCTIONAL T CELLS SPECIFIC OF HBV IN THE LIVER OF HBV PERSISTENT MICE IFN/TNF/IL2 ICS assays at day 47 on intrahepatic lymphocytes, after single TG1050 injection of C57BL/6J mice Number of cytokine positive CD8 T cells / test (1/5 of intrahepatic lymphocytes) PBS AAV-HBV AAV-HBV PB

  8. Slide 8: TG1050 induces anti-HBV core antibodies in HBV persistent mice

    TG1050 INDUCES ANTI-HBV CORE ANTIBODIES IN HBV PERSISTENT MICE Anti-HBc antibodies (ELISA) 4 (OD450nm , Mean +/- SEM) 3 Anti-HBc 2 * * 1 * * * * * 0 0 11 28 39 46 55 67 84 105 126 147 158 Days post AAV-HBV injection AAV-HBV C57BL/6J mice immunized at day D32, D54, D62, D68 with C57BL/6J mice immuniz

  9. Slide 9: TG1050 has a sustained antiviral effect in HBV persistent mice

    TG1050 HAS A SUSTAINED ANTIVIRAL EFFECT IN HBV PERSISTENT MICE : Significant decrease of HBV DNA and HBsAg levels HBV DNA (viral load) Circulating HBsAg Mean viral load at D28 : 1.4x106 copies/mL Mean HBsAg titers at D28 : 20µg/mL 10 2 HBsAg Fold Change HBV DNA Fold Change (Mean +/- SEM) (Mean +/- S

  10. Slide 10: TG1050 induces HBV DNA and HBsAg decline as well as HBsAg seroconversion

    TG1050 INDUCES HBV DNA AND HBSAG DECLINE AS WELL AS HBSAG SEROCONVERSION IN SOME HBV PERSISTENT MICE C57BL/6J mice 3.1 to 3.8 were HBV persistent and injected with TG1050 at days 32, 54, 62 and 68 (vertical dotted line) (log (copies/ml)) HBV-DNA LoQ LoD days log (ng/ml) HBsAG LoD days Anti HBs OD450

  11. Slide 11: Summary

    SUMMARY  In the AAV-HBV model in C57BL/6J mice, TG1050 in stand alone was shown to be able to induce :  HBV-specific functional T cells detected in the liver and producing cytokines  an antiviral activity, detected as soon as after the 1rst injection and which is sustained overtime  100% of trea

  12. Slide 12: Conclusion

    CONCLUSION In a context of HBV persistence, TG1050 is immunogenic, exerts an antiviral activity and triggers HBsAg seroconversion TG1050 is capable of capturing key features required to acheive clinical cure A Phase 1/1b (First-In-Man and dose finding) study is underway, with recruitment expected

  13. Slide 13: Acknowledgements

    ACKNOWLEDGEMENTS TRANSGENE HBV Research Team (Strasbourg and Lyon, France) INSTITUT PASTEUR, Paris, France, (HBV pathogenesis, INSERM U994) Smart Virus Lab and Smart Infectious Diseases Dpt • Maryline Bourgine Data Lab • Sarah Dion • Nathalie Silvestre • Geneviève Inchauspé • Ophélie Godon • Renée B

Transgene — EASL Liver Congress 2015 on 6ix